Indole-1-carboxamides for Multi-Kinase Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases related to unregulated tyrosine kinase signal transduction, such as cancer and blood vessel proliferative disorders, are limited in their ability to effectively inhibit tyrosine kinase activity across multiple pathways, leading to incomplete therapeutic effects.
Innovation Solution
Development of organic molecules, represented by Formula I, which can modulate and inhibit protein kinase RNA-activated (PKR) and tyrosine kinase signal transduction, targeting both receptor and non-receptor tyrosine kinases to regulate abnormal cell proliferation and vascular disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments target single tyrosine kinase pathways, then treatment specificity is maintained, but therapeutic effectiveness is insufficient due to inability to inhibit multiple pathways
Solution Approach 1:
The indole-1-carboxamide compounds are designed to function as universal inhibitors across multiple tyrosine kinase pathways. The molecular structure (Formula I) enables simultaneous inhibition of diverse kinases including VEGFR, PDGFR, and other receptor and non-receptor tyrosine kinases, allowing a single agent to address multiple disease mechanisms that single-pathway inhibitors cannot target
2Adaptability or versatility
If broad-spectrum tyrosine kinase inhibition is achieved, then therapeutic coverage is improved, but selectivity and potential off-target effects may be compromised
Solution Approach 1:
The compounds exhibit local quality through differential inhibition patterns where specific substituent configurations on the indole core selectively enhance or reduce activity against particular kinase families. By modifying R1-R7 substituents, the compound can be tuned to preferentially inhibit pathological kinases while sparing physiological ones, achieving pathway-specific effects within a broad-spectrum framework
3Reliability
If multiple tyrosine kinase pathways are inhibited simultaneously, then comprehensive disease treatment is achieved, but molecular complexity of the inhibitor increases
Solution Approach 1:
The patent merges multiple kinase inhibition capabilities into a single molecular entity—the indole-1-carboxamide core structure. Rather than requiring separate drugs for different pathways, the compound consolidates inhibition of VEGFR, PDGFR, and other kinases into one agent, simplifying treatment regimens while maintaining comprehensive pathway coverage
Data Source
AI summary
This invention is directed to a compound of Formula Ior a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.